Wesana Health Holdings Inc
Change company Symbol lookup
Select an option...
WSNAF Wesana Health Holdings Inc
ZEUS Olympic Steel Inc
EJH E-Home Household Service Holdings Ltd
AMZN Amazon.com Inc
BGTTF Goat Industries Ltd
BRDS Bird Global Inc
GHM Graham Corp
DRMA Dermata Therapeutics Inc
VGAS Verde Clean Fuels Inc
CURV Torrid Holdings Inc

Based in Canada
Company profile

Wesana Health Holdings Inc is a Canada-based life science company. The Company is engaged in development and delivery of psychedelic and naturally sourced therapies to treat traumatic brain Injury related depressive disorder, anxiety and migraines through drug development and predictive diagnostics. The Company is also engaged in care development through its therapies and patent-pending protocols, and in care delivery through activating a multidisciplinary, technology-supported clinical model. Its SANA-013 is a novel composition and method of use that provides sustained effects and benefit over time. The Company’s novel and proprietary depression treatment protocol that includes a single high dose of psilocybin followed by a maintenance regimen of a micro dose of psilocybin combined with cannabidiol, significantly reduced depressive behaviors in a validated animal model.

Closing Price
Day's Change
0.00 (0.00%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

Danaher sees Q4 sales increasing in 'low-single-digit percent range'

4:53 pm ET January 9, 2023 (MarketWatch)

Danaher Corp. (DHR) on Monday said it expected fourth-quarter sales to rise in the "low-single-digit percent range," despite what executives said was a "challenging environment" for the maker of diagnostic and life-sciences equipment. That forecast was more upbeat than FactSet's expectations for a 5% fourth-quarter sales decline to $7.71 billion. Shares rose 2% after hours. Chief Executive Rainer Blair said the company's core business saw "high-single-digit" revenue growth, while the molecular diagnostic business in Cepheid, which Danaher acquired in 2016, had "better than expected growth," with more than $1 billion in respiratory testing revenue. The company made the remarks ahead of a presentation at the J.P. Morgan Healthcare Conference, set for Tuesday.

-Bill Peters


(END) Dow Jones Newswires

January 09, 2023 16:53 ET (21:53 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.